FTC approves Valeant buy with asset sales
WASHINGTON (Reuters) - Antitrust regulators approved Valeant Pharmaceutical's (VRX.TO) acquisition of the dermatology units of Sanofi and Johnson & Johnson, on the condition that it sell the rights to three prescription drugs, the Federal Trade Commission said on Monday.
Valeant is in the process of acquiring Ortho Dermatologics, Inc. from Johnson & Johnson (JNJ.N), and Dermik Laboratories, Inc. from Sanofi Aventis SASY.PA..
TOKYO - Asian shares slipped on Tuesday as a U.S. holiday robbed markets of momentum, while the euro hit a fresh one-year low on uncertainty over the European Central Bank's policy decision later this week.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.